2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Diffuse Large B-Cell Lymphoma Refractory
1
Interventions
pembrolizumab
44
Carboplatin
40
Cisplatin
36
Paclitaxel
29
Nivolumab
24
Pemetrexed
24
Gemcitabine
23
Dexamethasone
21
Rituximab
18
Ipilimumab
16
Cyclophosphamide
15
Capecitabine
14
Fluorouracil
14
Docetaxel
13
atezolizumab
13
Lenalidomide
12
Trastuzumab
12
durvalumab
12
trastuzumab deruxtecan
12
Cytarabine
11
daratumumab
11
130-nm albumin-bound paclitaxel
10
Bevacizumab
10
Bortezomib
10
Prednisone
10
olaparib
10
Doxorubicin
9
Crizotinib
8
Oxaliplatin
8
venetoclax
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
loncastuximab tesirine
×
Clear all
NCT03589469
2023-08-29
LOTIS-2
ADC Therapeutics S.A.
Phase 2
Completed
145 enrolled
24 charts
1 FDA